Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Tenax Therapeutics (TENX) EBIT (2016 - 2017)

Tenax Therapeutics' EBIT history spans 8 years, with the latest figure at -$17.0 million for Q4 2017.

  • For Q4 2017, EBIT rose 74.78% year-over-year to -$17.0 million; the TTM value through Dec 2017 reached -$9.2 million, up 88.83%, while the annual FY2025 figure was -$56.4 million, 189.24% down from the prior year.
  • EBIT for Q4 2017 was -$17.0 million at Tenax Therapeutics, down from $1.3 million in the prior quarter.
  • Across five years, EBIT topped out at $3.5 million in Q1 2017 and bottomed at -$67.5 million in Q4 2016.
  • The 5-year median for EBIT is -$4.7 million (2016), against an average of -$11.7 million.
  • The largest annual shift saw EBIT plummeted 184.94% in 2013 before it skyrocketed 164.53% in 2017.
  • A 5-year view of EBIT shows it stood at -$1.6 million in 2013, then crashed by 680.78% to -$12.4 million in 2014, then plummeted by 89.09% to -$23.5 million in 2015, then crashed by 187.39% to -$67.5 million in 2016, then soared by 74.78% to -$17.0 million in 2017.
  • Per Business Quant, the three most recent readings for TENX's EBIT are -$17.0 million (Q4 2017), $1.3 million (Q3 2017), and $3.0 million (Q2 2017).